Turning to Wall Street, the analysts’ consensus rating for Praxis Precision Medicines is Strong Buy, based on 10 Buy and a single Sell rating over the past three months. With that comes an average ...
Praxis Precision Medicines (PRAX) stock surges as its movement disorder therapy ulixacaltamide succeeds in two Phase 3 trials in essential tremor. Read more here.
The average one-year price target for Praxis Precision Medicines (NasdaqGS:PRAX) has been revised to $258.64 / share. This is ...
Praxis Precision Medicines has shared positive data from its Phase III Essential3 clinical trial program (NCT06087276) assessing ulixacaltamide in essential tremor (ET). Across two studies, the small ...
Praxis Precision Medicines, Inc. announced positive topline results from its Phase 3 Essential3 program evaluating ulixacaltamide for essential tremor , the most movement disorder.Praxis stock ...
Patients treated with ulixacaltamide in the parallel-group study (Study 1) showed a mean improvement from baseline in the Modified Activities of ...
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, ...
BOSTON, May 11, 2023 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for ...
If you have been paying any attention to Praxis Precision Medicines lately, you have probably noticed the ticker’s rollercoaster ride. Over the past week alone, shares have skyrocketed by an ...
CANOGA PARK, Calif., Sept. 14 /PRNewswire/ -- Praxis EMR has submitted its application to the Drummond Group, making it among the first EMRs to apply for HITECH certification in the country. Under the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback